Literature DB >> 8805034

Insulin-like growth factor system components and the coupling of bone formation to resorption.

S Mohan1, D J Baylink.   

Abstract

In the adult skeleton, bone formation is regulated by an event referred to as the coupling of bone formation to resorption (i.e. formation is quantitatively linked to resorption), which is thought to be mediated in part by osteogenic growth factor molecules produced by bone cells. Of the various osteogenic growth factors identified in bone, there is sufficient evidence to document an important role for the insulin-like growth factor (IGF) system in mediating this coupling process. Studies on the basic aspects of the IGF system reveal that it is complex and involves a number of components which include the inhibitory IGF binding protein (IGFBP)-4 and stimulatory IGFBP-5 and their corresponding proteases. This complex regulatory scheme of the IGF component system, together with the finding that all of the IGF system components are regulated in bone cells by both local and systemic effectors of bone metabolism, underscores the importance of the IGFs in mediating coupling of bone formation to resorption. In addition, a number of in vitro and in vivo findings also suggest that the IGF system could play a role in the positive (net gain of bone) or negative (net loss of bone) uncoupling of bone formation to resorption.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8805034     DOI: 10.1159/000184833

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  18 in total

Review 1.  The multi-functional role of insulin-like growth factor binding proteins in bone.

Authors:  Kristen E Govoni; David J Baylink; Subburaman Mohan
Journal:  Pediatr Nephrol       Date:  2004-11-11       Impact factor: 3.714

Review 2.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

Review 3.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

Review 4.  Coupling factors involved in preserving bone balance.

Authors:  Beom-Jun Kim; Jung-Min Koh
Journal:  Cell Mol Life Sci       Date:  2018-12-04       Impact factor: 9.261

5.  Effects of systemic and local administration of recombinant human IGF-I (rhIGF-I) on de novo bone formation in an aged mouse model.

Authors:  John L Fowlkes; Kathryn M Thrailkill; Lichu Liu; Elizabeth C Wahl; Robert C Bunn; Gael E Cockrell; Daniel S Perrien; James Aronson; Charles K Lumpkin
Journal:  J Bone Miner Res       Date:  2006-09       Impact factor: 6.741

6.  Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation.

Authors:  Yousef G Amaar; David J Baylink; Subburaman Mohan
Journal:  J Bone Miner Res       Date:  2005-03-14       Impact factor: 6.741

7.  Lactoferrin promote primary rat osteoblast proliferation and differentiation via up-regulation of insulin-like growth factor-1 expression.

Authors:  Jian-ming Hou; Man Wu; Qing-ming Lin; Fan Lin; Ying Xue; Xu-hua Lan; En-yu Chen; Mei-li Wang; Hai-yan Yang; Feng-xiong Wang
Journal:  Mol Biol Rep       Date:  2014-05-03       Impact factor: 2.316

Review 8.  Disorders of bone remodeling.

Authors:  Xu Feng; Jay M McDonald
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

Review 9.  Serum insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 levels in aging and age-associated diseases.

Authors:  S Mohan; D J Baylink
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

10.  Identification and characterization of novel IGFBP5 interacting protein: evidence IGFBP5-IP is a potential regulator of osteoblast cell proliferation.

Authors:  Yousef G Amaar; Blanca Tapia; Shin-Tai Chen; David J Baylink; Subburaman Mohan
Journal:  Am J Physiol Cell Physiol       Date:  2005-11-02       Impact factor: 4.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.